Abstract 212P
Background
ERBB2 alterations are potential candidates for targeted treatments in metastatic urothelial cancer (UC). Recent data suggest that HER2-targeted antibody-drug conjugate (ADC) treatment is efficacious. Here, we explore the role of ERBB2 in UC by analyzing genomics in a large database of real-world patients.
Methods
Tumor tissues from 1112 Chinese patients with UC were evaluated by comprehensive genomic profiling for alterations in 808 cancer-related genes. Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements.
Results
Of 1112 cases, 167 (15.0%) featured ERBB2 genomic alterations (GAs), including 82 (7.4%) ERBB2 mutations (ERBB2mut), 41 (3.7%) ERBB2 amplifications (ERBB2amp) and 44 (4.0%) cases had co-occurring ERBB2 GAs. ERBB2mut was not mutually exclusive of ERBB2amp which occurred in up to 43.2% of co-altered cases. The top mutated ERBB2 SNVs/indels were p.S310F/Y (32, 21.2%) and p.L755S (7, 4.6%). ERBB2mut predominantly affected the kinase (49, 32.5%) or extracellular (69, 45.7%) domains. Genes commonly co-altered with ERBB2 were TERT (68.9%), ARID1A(37.1%), RB1 (28.7%), KMT2C (26.9%) and ATM (24.6%). Other significantly higher mutation frequency for genes were TP53, APC, SMARCA4, NF1, ERBB3, ERCC2, EGFR and MTOR (p＜0.05) in ERBB2 GAs cases. Significantly lower rates of CDKN2B were found in ERBB2 GAs compared with ERBB2 wild type (22.0% vs 12.0%, p＜0.01). CDK12 was the most common co-amplification gene with ERBB2amp (p＜0.01). FGFR3 mutations were significantly enriched in ERBB2mut than ERBB2amp (p=0.04). Patients with ERBB2 GAs were significantly more likely to have high tumor mutational burden (p＜0.01).
Conclusions
The study provided the landscape of ERBB2 alterations in UC that may benefit from anti-HER2 agents. Consideration should be given to developing trials inclusive of patients with UC harboring ERBB2 alterations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract